Dupixent® (dupilumab) – New drug approval
March 28, 2017 – Sanofi and Regeneron announced the FDA approval of Dupixent (dupilumab) for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Top